Eihab Akary, MD
Urology · Manteca
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Office
- 1
- Since medical school
- 12 years
- University of South Florida College of Medicine, 2014
Offices
1 location · First Choice Physician Partners · 130 clinicians in this group
Hospitals listed: Doctors Hospital of Manteca · Doctors Medical Center · Memorial Medical Center · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Akary’s office at (209) 823-7646 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
State licence records
1 licence
- Florida ME139247Medical Doctor · since 2019 · expires 2027-01-31ActiveNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Education
- University of South Florida2010–2014
Hospitals they work in
4 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Doctors Hospital of MantecaManteca, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency departmentPart of Tenet Healthcare, which runs 77 hospitals in 12 statesPatients rate it 2 of 5 · 55% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.165, Oct 2024 – Sep 2025
- Doctors Medical CenterModesto, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of Tenet Healthcare, which runs 77 hospitals in 12 statesPatients rate it 2 of 5 · 59% would definitely recommend itOverall rating: 1 of 5 starsWorse than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 1.36 (1.02 to 1.71), Jul 2022 – Jun 2024Worse than the national rate — Pressure ulcer rate: 1.35 (0.81 to 1.9) · 6,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.281, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.326, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.183, Oct 2024 – Sep 2025
- Memorial Medical CenterModesto, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 72% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.093, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.085, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Doctors Hospital of Manteca
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 0 better, 2 the same, 0 worse of 2 measures. Readmissions: 0 better, 4 the same, 2 worse of 6 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.165 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.01 (0 to 2.09) · 230 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.96 (0.49 to 1.42) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 30 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.5 · 110 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 172 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.7 · 81 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.5 · 700 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.33 (0.1 to 0.56) · 1,428 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.26 (0.05 to 0.47) · 1,462 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.82 (1.24 to 6.39) · 137 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.28 (0.57 to 4) · 130 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.75 (0.23 to 3.28) · 58 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.41 (0 to 1.49) · 1,152 cases | No different | Jul 2022 – Jun 2024 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.4 · 173 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 67.3 · 110 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 60 · 183 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.4 · 250 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.8 · 48 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.5 (9.2 to 16.8) · 379 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.5) · 52 cases | No different | Jan 2024 – Dec 2024 |
What patients said (339 patients answered, 15% of those asked)
| Cleanliness | 3 |
| Nurse communication | 1 |
| Doctor communication | 1 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 2 |
| Room was "always" clean | 68% |
| Nurses "always" communicated well | 69% |
| Doctors "always" communicated well | 68% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 81% |
| Yes, staff "did" give patients information about help after discharge | 77% |
| Doctors "always" explained things so they could understand | 62% |
| Doctors "always" listened carefully | 65% |
| Doctors "always" treated them with courtesy and respect | 76% |
| Patients who gave a rating of "9" or "10" (high) | 56% |
| Staff "always" explained new medications | 69% |
| Nurses "always" explained things so they could understand | 62% |
| Nurses "always" listened carefully | 65% |
| Nurses "always" treated them with courtesy and respect | 79% |
| "Always" quiet at night | 39% |
| "YES", patients would definitely recommend the hospital | 55% |
| Staff "always" explained possible side effects | 42% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
See every measure and the patient survey for Doctors Medical Center
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 2 better, 3 the same, 1 worse of 6 measures. Readmissions: 0 better, 5 the same, 3 worse of 8 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.36 (1.02 to 1.71) | Worse | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 1.35 (0.81 to 1.9) · 6,296 cases | Worse | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.281 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.326 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.183 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.27 (0.31 to 2.23) · 1,396 cases | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 183.31 (147.26 to 219.36) · 127 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 4.1 · 135 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 10.1 · 95 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 15.2 · 276 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 12.8 · 321 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.2 · 364 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 12.9 · 767 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.6 · 3,719 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.37) · 7,050 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.24 (0.05 to 0.43) · 7,169 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.12 (2.19 to 6.06) · 1,622 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.6 (0 to 3.3) · 48 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.63 (1.23 to 4.04) · 1,601 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 14.79 (5.73 to 23.85) · 51 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.99 (0.75 to 9.23) · 51 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.65 (0.17 to 3.13) · 242 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.9 · 67 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.484 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.582 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.3 · 424 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 24 · 682 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 36.6 · 326 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 70.5 · 378 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 366 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.2 · 564 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 70 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 14.7 · 120 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.1 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.5 (9.4 to 16.4) · 573 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.3 (1 to 1.7) · 303 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,045 patients answered, 15% of those asked)
| Cleanliness | 2 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 2 |
| Room was "always" clean | 63% |
| Nurses "always" communicated well | 72% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 67% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 57% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 67% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 36% |
| "YES", patients would definitely recommend the hospital | 59% |
| Staff "always" explained possible side effects | 42% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Memorial Medical Center
Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 9 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.093 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.085 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.3 (0.41 to 2.2) · 2,271 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.75 to 1.3) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 185.77 (144.66 to 226.88) · 146 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 3.2 · 105 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.2 · 237 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 14.1 · 194 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 12.9 · 513 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.4 · 640 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.3 · 278 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.5 · 4,882 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.03 to 0.42) · 10,183 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 10,422 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.4 (1.58 to 5.23) · 2,596 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.92 (0.45 to 3.38) · 845 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 3.1 (1.78 to 4.42) · 2,439 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.71 (5.69 to 17.72) · 885 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.28 (3.75 to 10.81) · 829 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.82 (0.4 to 3.24) · 563 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.2 (0 to 0.72) · 9,080 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.4 · 283 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.389 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.485 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.507 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15 · 255 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.9 · 849 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 19.2 · 201 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -8.4 · 584 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 26.6 · 660 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.9 · 895 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.8 (3.3 to 6.9) · 285 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11 (8.4 to 14.3) · 285 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.9 · 273 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.7 · 108 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.4 · 341 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.9 (10.2 to 16.1) · 2,334 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 717 cases | No different | Jan 2024 – Dec 2024 |
What patients said (655 patients answered, 19% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 72% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 74% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 44% |
| "YES", patients would definitely recommend the hospital | 72% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$138,558
Medicare paid this office $138,558 for 649 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 101 | $26,875 | $91 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 126 | $17,334 | $133 |
| Short return visit (20+ min) | 195 | $15,815 | $71 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 103 | $15,223 | $61 |
| Return visit (30+ min) | 112 | $8,283 | $69 |
See all 14 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 101 | $26,875 | $91 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 126 | $17,334 | $133 |
| Short return visit (20+ min) | 195 | $15,815 | $71 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 103 | $15,223 | $61 |
| Return visit (30+ min) | 112 | $8,283 | $69 |
| Diagnostic exam of bladder and urethra using an endoscope | 41 | $7,556 | $180 |
| New patient visit (30+ min) | 77 | $6,829 | $89 |
| New patient visit (45+ min) | 36 | $3,143 | $87 |
| Biopsy of prostate gland | 11 | $2,067 | $188 |
| Simple insertion of temporary bladder tube | 25 | $1,876 | $51 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 15 | $1,520 | $101 |
| Short return visit | 31 | $1,341 | $43 |
| Ultrasound measurement of bladder capacity after voiding | 58 | $445 | $7 |
| Imaging of urinary tract following injection of a contrast agent | 14 | $265 | $19 |
Procedures Medicare counted
| Prostate resection | 39 | More than 94% of doctors who do this |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Ultrasound measurement of bladder capacity after voiding | 88 | 240 | 395 | 397 | 359 | 60 |
| Diagnostic exam of bladder and urethra using an endoscope | 19 | 76 | 99 | 97 | 111 | 42 |
| Electronic assessment of bladder emptying | 24 | 71 | 138 | 79 | 105 | – |
| Insertion of stent in ureter using an endoscope | – | 58 | 38 | 32 | 29 | – |
| Simple insertion of temporary bladder tube | 15 | 29 | 29 | 24 | 18 | 37 |
| Instillation of anti-cancer drug into bladder | – | 86 | – | 58 | – | – |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
649 Original Medicare patients in 2024. Average age 76 · Under 65 8% · 85 and older 18% · Women 31% · Also on Medicaid 27% · Health risk score 1.86. Above the middle of the specialty; the typical urology clinician is at 1.36.
Conditions among them: High blood pressure 75% · Coronary heart disease 42% · Diabetes 41% · Chronic kidney disease 40% · Depression 32% · COPD 27% · Atrial fibrillation 26% · Heart failure 25% · Cancer 22% · Dementia 16% · Stroke 14%.
The office billed $431,767, Medicare allowed $183,091 and paid $138,558; for 3,703 services of 71 kinds; $3,718 of it was for drugs given in the office and $134,840 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 649 | 3,703 | 76 | 1.86 | $431,767 | $138,558 |
| 2023 | 963 | 7,855 | 78 | 1.87 | $953,272 | $352,198 |
| 2022 | 699 | 6,123 | 77 | 1.59 | $1,082,414 | $347,264 |
| 2021 | 539 | 4,320 | 76 | 1.64 | $1,206,054 | $280,107 |
| 2020 | 541 | 4,161 | 77 | 1.75 | $1,202,710 | $262,458 |
| 2019 | 186 | 1,164 | 78 | 1.51 | $264,927 | $61,894 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 29 services
| Return visit (30+ min) | 365 | $64,574 | $95 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 372 | $55,049 | $140 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 220 | $38,841 | $96 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 245 | $31,966 | $64 |
| Diagnostic exam of bladder and urethra using an endoscope | 102 | $18,997 | $171 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 18 | $18,872 | None |
| New patient visit (45+ min) | 146 | $18,631 | $128 |
| Shock wave crushing of kidney stones | 20 | $11,677 | $449 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 20 | $10,405 | $520 |
| Short return visit (20+ min) | 81 | $6,224 | $72 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 18 | $5,463 | $273 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 44 | $4,757 | $106 |
| Simple change of bladder tube | 13 | $3,393 | $71 |
| Insertion of implant in urethra within prostate gland using an endoscope, 1 implant | 18 | $2,848 | $158 |
| Ultrasound measurement of bladder capacity after voiding | 239 | $2,838 | $8 |
| Insertion of stent in ureter using an endoscope | 27 | $2,780 | $96 |
| Insertion of implant in urethra within prostate gland using an endoscope, each additional implant | 18 | $2,510 | $41 |
| Biopsy of prostate gland | 19 | $2,218 | $106 |
| New patient visit (30+ min) | 21 | $1,887 | $90 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 28 | $1,786 | $41 |
| Electronic assessment of bladder emptying | 90 | $1,055 | $10 |
| Imaging of urinary tract following injection of a contrast agent | 38 | $1,022 | $20 |
| Simple insertion of temporary bladder tube | 14 | $864 | $48 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 18 | $739 | $25 |
| Ultrasonic guidance for needle placement | 15 | $697 | $44 |
| Automated urinalysis test | 194 | $631 | $2 |
| Ultrasound scan of pelvic region through rectum | 13 | $385 | $26 |
| Injection of drug or substance under skin or into muscle | 20 | $301 | $11 |
| Injection, ceftriaxone sodium, per 250 mg | 18 | $64 | None |
2022: 31 services
| Return visit (30+ min) | 390 | $70,186 | $92 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 144 | $28,404 | $81 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 151 | $25,779 | $156 |
| New patient visit (45+ min) | 172 | $21,345 | $124 |
| Diagnostic exam of bladder and urethra using an endoscope | 85 | $18,175 | $187 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 29 | $16,679 | $575 |
| Shock wave crushing of kidney stones | 26 | $14,554 | $441 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 113 | $12,609 | $56 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 13 | $10,643 | None |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 47 | $5,287 | $104 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 16 | $5,202 | $325 |
| Removal of bladder neck through urethra | 21 | $4,181 | $199 |
| Instillation of anti-cancer drug into bladder | 12 | $3,845 | $66 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 13 | $3,634 | $242 |
| Insertion of stent in ureter using an endoscope | 28 | $3,131 | $98 |
| Ultrasound measurement of bladder capacity after voiding | 254 | $2,989 | $8 |
| Long return visit (40+ min) | 18 | $2,204 | $116 |
| Short return visit (20+ min) | 27 | $1,871 | $67 |
| Biopsy of prostate gland | 16 | $1,582 | $99 |
| Insertion of implant in urethra within prostate gland using an endoscope, each additional implant | 11 | $1,461 | $41 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 16 | $1,224 | $77 |
| Simple insertion of temporary bladder tube | 18 | $1,040 | $43 |
| Imaging of urinary tract following injection of a contrast agent | 35 | $983 | $20 |
| Automated urinalysis test | 252 | $781 | $2 |
| Electronic assessment of bladder emptying | 68 | $740 | $9 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 15 | $541 | $25 |
| Ultrasound scan of pelvic region through rectum | 13 | $335 | $26 |
| Ultrasonic guidance for needle placement | 12 | $317 | $26 |
| Urinalysis, manual test | 48 | $247 | $3 |
| Injection of drug or substance under skin or into muscle | 16 | $246 | $11 |
| Injection, ceftriaxone sodium, per 250 mg | 14 | $30 | None |
2021: 30 services
| Return visit (30+ min) | 367 | $80,482 | $96 |
| Injection, triptorelin pamoate, 3.75 mg | 11 | $27,849 | None |
| New patient visit (45+ min) | 151 | $18,716 | $124 |
| Diagnostic exam of bladder and urethra using an endoscope | 87 | $18,070 | $183 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 30 | $11,469 | $337 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 18 | $10,796 | $600 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 11 | $9,398 | None |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 72 | $7,967 | $108 |
| Shock wave crushing of kidney stones | 15 | $6,998 | $467 |
| Long return visit (40+ min) | 35 | $5,812 | $145 |
| Insertion of stent in ureter using an endoscope | 35 | $4,080 | $107 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 13 | $3,812 | $293 |
| Removal of bladder neck through urethra | 18 | $3,620 | $201 |
| Ultrasound measurement of bladder capacity after voiding | 240 | $2,976 | $8 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 12 | $2,678 | $223 |
| Insertion of implant in urethra within prostate gland using an endoscope, 1 implant | 11 | $1,832 | $167 |
| Insertion of device into abdomen with pressure and urine flow rate study | 12 | $1,763 | $147 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 19 | $1,641 | $82 |
| Simple insertion of temporary bladder tube | 20 | $1,416 | $49 |
| Electronic assessment of bladder emptying | 110 | $1,300 | $9 |
| Imaging of urinary tract following injection of a contrast agent | 46 | $1,282 | $20 |
| Insertion of implant in urethra within prostate gland using an endoscope, each additional implant | 11 | $1,277 | $43 |
| Simple bladder irrigation and/or instillation | 17 | $1,077 | $60 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 22 | $894 | $31 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 14 | $808 | $58 |
| Complicated insertion of bladder tube | 11 | $694 | $63 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 17 | $561 | $23 |
| Urinalysis, manual test | 68 | $345 | $3 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 12 | $306 | $25 |
| Automated urinalysis test | 81 | $257 | $2 |
2020: 31 services
| Return visit (30+ min) | 309 | $60,497 | $83 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 128 | $22,236 | $161 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 14 | $20,142 | None |
| New patient visit (45+ min) | 138 | $17,124 | $124 |
| Diagnostic exam of bladder and urethra using an endoscope | 66 | $12,594 | $166 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 32 | $12,238 | $340 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 71 | $9,101 | $83 |
| Shock wave crushing of kidney stones | 14 | $7,082 | $472 |
| Insertion of stent in ureter using an endoscope | 47 | $6,229 | $107 |
| Instillation of anti-cancer drug into bladder | 12 | $5,721 | $67 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 40 | $4,410 | $110 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 15 | $3,493 | $233 |
| Initial hospital observation care per day, typically 70 minutes | 22 | $3,195 | $139 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 33 | $2,649 | $59 |
| Crushing of stone of ureter using an endoscope | 19 | $1,992 | $95 |
| Imaging of urinary tract following injection of a contrast agent | 52 | $1,841 | $20 |
| Ultrasound measurement of bladder capacity after voiding | 164 | $1,812 | $8 |
| Biopsy of prostate gland | 14 | $1,655 | $110 |
| Simple bladder irrigation and/or instillation | 20 | $1,632 | $58 |
| Simple insertion of temporary bladder tube | 17 | $1,361 | $47 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 11 | $924 | $84 |
| Complicated insertion of bladder tube | 12 | $848 | $65 |
| Electronic assessment of bladder emptying | 65 | $680 | $10 |
| Manual urinalysis test with examination using microscope, automated | 117 | $539 | $3 |
| Automated urinalysis test | 142 | $527 | $2 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 15 | $519 | $24 |
| Ultrasound scan of pelvic region through rectum | 14 | $436 | $27 |
| Ultrasonic guidance for needle placement | 14 | $390 | $26 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 14 | $288 | $18 |
| Imaging guidance for procedure, 60 minutes or less | 12 | $178 | $13 |
| Injection of drug or substance under skin or into muscle | 12 | $147 | $11 |
2019: 10 services
| Return visit (30+ min) | 89 | $12,311 | $85 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 35 | $5,662 | $162 |
| New patient visit (45+ min) | 44 | $5,649 | $128 |
| Long return visit (40+ min) | 37 | $4,365 | $115 |
| Diagnostic exam of bladder and urethra using an endoscope | 19 | $2,831 | $149 |
| Ultrasound measurement of bladder capacity after voiding | 64 | $853 | $10 |
| Simple insertion of temporary bladder tube | 11 | $729 | $49 |
| Manual urinalysis test with examination using microscope, automated | 60 | $238 | $3 |
| Electronic assessment of bladder emptying | 23 | $230 | $10 |
| Automated urinalysis test | 30 | $85 | $2 |
Medicaid work
$35,439 in 2024
Medicaid paid $35,439 for 547 billed services this clinician did in 2024, up to 41 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Clinic visit/encounter, all-inclusive | 192 | $34,566 |
| Short return visit (20+ min) | 126 | $599 |
| Short return visit | 30 | $217 |
| New patient visit (30+ min) | 25 | $57 |
| Medication list documented in medical record (COA) | 60 | $0 |
| Review of all medications by a prescribing practitioner or clinical pharmacist (such as, prescriptions, OTCs, herbal therapies and supplements) documented in the medical record (COA) | 55 | $0 |
| BODY MASS INDEX DOCD | 59 | $0 |
| 2024 | 547 | 7 | 41 | $35,439 |
| 2023 | 487 | 6 | 51 | $38,503 |
| 2022 | 13 | 1 | 13 | $1,552 |
| 2021 | 94 | 1 | 16 | $5,571 |
| 2020 | 83 | 1 | 15 | $3,017 |
See the largest Medicaid services in earlier years
2023
| Clinic visit/encounter, all-inclusive | 234 | $37,307 |
| Short return visit (20+ min) | 154 | $896 |
| Return visit (30+ min) | 33 | $300 |
| Medication list documented in medical record (COA) | 41 | $0 |
| Review of all medications by a prescribing practitioner or clinical pharmacist (such as, prescriptions, OTCs, herbal therapies and supplements) documented in the medical record (COA) | 12 | $0 |
| BODY MASS INDEX DOCD | 13 | $0 |
2022
| Clinic visit/encounter, all-inclusive | 13 | $1,552 |
2021
| Return visit (30+ min) | 94 | $5,571 |
2020
| Return visit (30+ min) | 83 | $3,017 |
Drugs they prescribed that Part D paid
$64,438
Pharmacies billed $64,438 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
719 generic and 56 brand-name prescriptions · $64,438 in drug cost · 115 antibiotic prescriptions to 98 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Myrbetriq | 22 | $19,259 | $875 |
| Tamsulosin | 309 | $4,452 | $14 |
| Estradiol | 36 | $2,857 | $79 |
| Bicalutamide | 49 | $2,596 | $53 |
| Methenamine Hippurate | 14 | $1,239 | $88 |
See all 13 drugs
| Myrbetriq | 22 | $19,259 | $875 |
| Tamsulosin | 309 | $4,452 | $14 |
| Estradiol | 36 | $2,857 | $79 |
| Bicalutamide | 49 | $2,596 | $53 |
| Methenamine Hippurate | 14 | $1,239 | $88 |
| Finasteride | 65 | $907 | $14 |
| Oxybutynin Chloride | 29 | $776 | $27 |
| Alfuzosin Hcl Er | 31 | $532 | $17 |
| Nitrofurantoin Mono-Macro | 40 | $436 | $11 |
| Testosterone Cypionate | 13 | $384 | $30 |
| Clotrimazole-Betamethasone | 12 | $273 | $23 |
| Ciprofloxacin | 49 | $191 | $4 |
| Cefdinir | 14 | $92 | $7 |
Year by year
| 2024 | 775 | 368 | None | 7% | $64,438 |
| 2023 | 1,435 | 533 | None | 12% | $318,560 |
| 2022 | 1,344 | 462 | None | None | $211,230 |
| 2021 | 1,370 | 446 | 2% (24) | None | $77,995 |
| 2020 | 862 | 290 | None | 10% | $36,539 |
| 2019 | 181 | 81 | None | None | $19,352 |
| 2018 | 87 | 51 | None | 15% | $4,108 |
| 2017 | 32 | 20 | None | None | $400 |
| 2016 | 130 | 78 | 34% (44) | None | $1,920 |
| 2015 | 41 | 15 | 27% (11) | None | $699 |
| 2014 | 47 | 26 | 53% (25) | None | $1,586 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 19 drugs
| Xiaflex | 18 | $226,843 | $12,602 |
| Myrbetriq | 35 | $27,524 | $786 |
| Tamsulosin | 482 | $8,710 | $18 |
| Potassium Citrate Er | 40 | $6,764 | $169 |
| Estradiol | 59 | $5,511 | $93 |
| Bicalutamide | 78 | $4,795 | $61 |
| Methenamine Hippurate | 16 | $3,452 | $216 |
| Nitrofurantoin Mono-Macro | 213 | $2,742 | $13 |
| Testosterone | 21 | $2,087 | $99 |
| Testosterone Cypionate | 31 | $1,774 | $57 |
| Finasteride | 111 | $1,736 | $16 |
| Alfuzosin Hcl Er | 49 | $1,409 | $29 |
| Oxybutynin Chloride | 42 | $1,062 | $25 |
| Tadalafil | 17 | $702 | $41 |
| Clotrimazole-Betamethasone | 13 | $606 | $47 |
| Ciprofloxacin | 58 | $288 | $5 |
| Oxybutynin Chloride Er | 16 | $281 | $18 |
| Cefdinir | 20 | $274 | $14 |
| Sulfamethoxazole-Trimethoprim | 17 | $56 | $3 |
2022: 19 drugs
| Xiaflex | 11 | $136,334 | $12,394 |
| Myrbetriq | 48 | $31,343 | $653 |
| Tamsulosin | 446 | $7,141 | $16 |
| Estradiol | 53 | $5,313 | $100 |
| Methenamine Hippurate | 34 | $3,844 | $113 |
| Bicalutamide | 68 | $3,705 | $54 |
| Potassium Citrate Er | 27 | $3,583 | $133 |
| Testosterone | 11 | $3,237 | $294 |
| Nitrofurantoin Mono-Macro | 172 | $2,179 | $13 |
| Finasteride | 111 | $1,924 | $17 |
| Alfuzosin Hcl Er | 42 | $1,291 | $31 |
| Tadalafil | 17 | $1,186 | $70 |
| Oxybutynin Chloride | 39 | $1,051 | $27 |
| Testosterone Cypionate | 17 | $902 | $53 |
| Solifenacin | 14 | $852 | $61 |
| Trospium Chloride | 14 | $653 | $47 |
| Ciprofloxacin | 86 | $562 | $7 |
| Cefdinir | 23 | $345 | $15 |
| Meloxicam | 46 | $153 | $3 |
2021: 19 drugs
| Myrbetriq | 56 | $36,714 | $656 |
| Estradiol | 70 | $7,968 | $114 |
| Tamsulosin | 461 | $6,944 | $15 |
| Testosterone | 12 | $6,240 | $520 |
| Bicalutamide | 66 | $3,467 | $53 |
| Methenamine Hippurate | 22 | $2,017 | $92 |
| Nitrofurantoin Mono-Macro | 188 | $1,980 | $11 |
| Finasteride | 65 | $1,794 | $28 |
| Oxybutynin Chloride | 58 | $1,468 | $25 |
| Testosterone Cypionate | 12 | $987 | $82 |
| Clotrimazole-Betamethasone | 25 | $951 | $38 |
| Trospium Chloride | 14 | $823 | $59 |
| Tadalafil | 13 | $703 | $54 |
| Cefdinir | 25 | $528 | $21 |
| Ciprofloxacin | 68 | $371 | $5 |
| Meloxicam | 93 | $328 | $4 |
| Alfuzosin Hcl Er | 11 | $324 | $29 |
| Oxycodone-Acetaminophen | 17 | $126 | $7 |
| Sulfamethoxazole-Trimethoprim | 12 | $41 | $3 |
2020: 11 drugs
| Myrbetriq | 19 | $10,455 | $550 |
| Tamsulosin | 333 | $4,793 | $14 |
| Estradiol | 27 | $3,851 | $143 |
| Bicalutamide | 47 | $2,346 | $50 |
| Nitrofurantoin Mono-Macro | 93 | $1,393 | $15 |
| Oxybutynin Chloride | 34 | $822 | $24 |
| Finasteride | 22 | $536 | $24 |
| Cefdinir | 25 | $448 | $18 |
| Ciprofloxacin | 83 | $323 | $4 |
| Meloxicam | 45 | $185 | $4 |
| Sulfamethoxazole-Trimethoprim | 44 | $102 | $2 |
2019: 4 drugs
| Tamsulosin | 57 | $683 | $12 |
| Bicalutamide | 17 | $634 | $37 |
| Ciprofloxacin | 23 | $149 | $6 |
| Meloxicam | 12 | $49 | $4 |
2018: 1 drug
| Ciprofloxacin | 23 | $55 | $2 |
2016: 4 drugs
| Tamsulosin | 14 | $437 | $31 |
| Oxybutynin Chloride | 22 | $358 | $16 |
| Oxycodone-Acetaminophen | 32 | $322 | $10 |
| Ciprofloxacin | 18 | $90 | $5 |
Money from drug and device companies
$1,202 in 2025
| 2025 | 5 | 12 | None | $1,202 |
| 2024 | 6 | 7 | None | $167 |
| 2023 | 15 | 33 | None | $949 |
| 2022 | 7 | 24 | None | $1,539 |
| 2021 | 6 | 17 | None | $359 |
| 2020 | 7 | 10 | None | $312 |
| 2019 | 8 | 20 | None | $665 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Teleflex | Barrigel | $882 | 3 payments
|
| Boston Scientific | Rezum Generator | $221 | 4 payments
|
| Laborie Medical Technologies | None | $44 | 2 payments
|
| Urogen Pharma | Zusduri | $38 | 2 payments
|
| Ge Healthcare | None | $17 | 1 payment
|
See all 12 published payments
| Laborie Medical Technologies | Meals · 2025-12-05 | None | $18 |
| Urogen Pharma | Meals · 2025-11-21 | Zusduri | $23 |
| Teleflex | Meals · 2025-11-08 | Barrigel | $526 |
| Teleflex | Travel · 2025-11-08 | Barrigel | $247 |
| Urogen Pharma | Meals · 2025-09-20 | Zusduri | $15 |
| Laborie Medical Technologies | Meals · 2025-08-22 | None | $26 |
| Boston Scientific | Meals · 2025-08-02 | Rezum Generator | $38 |
| Boston Scientific | Meals · 2025-07-18 | Rezum Generator | $32 |
| Teleflex | Meals · 2025-06-26 | Barrigel | $109 |
| Boston Scientific | Meals · 2025-06-25 | Spaceoar Vue System - 10ml | $97 |
| Boston Scientific | Meals · 2025-06-18 | Rezum Generator | $54 |
| Ge Healthcare | Meals · 2025-04-30 | None | $17 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $167
| Endo Pharmaceuticals | Xiaflex | $44 | 2 payments
|
| Boston Scientific | Rezum Generator | $30 | 1 payment
|
| Pfizer | Xtandi | $29 | 1 payment
|
| Teleflex | Urolift | $23 | 1 payment
|
| Becton Dickinson and | Arista Ah Flexitip | $22 | 1 payment
|
| Sumitomo Pharma America | Orgovyx | $18 | 1 payment
|
2023: $949
| Teleflex | Urolift | $207 | 4 payments
|
| Endo Pharmaceuticals | Xiaflex | $193 | 11 payments
|
| Dornier MedTech America | Dornier Medtech | $167 | 1 payment
|
| Boston Scientific | Rezum Generator | $104 | 2 payments
|
| Merck Sharp & Dohme | Keytruda | $54 | 3 payments
|
| Supernus Pharmaceuticals | Xyosted | $41 | 2 payments
|
| Astellas Pharma US | Myrbetriq | $29 | 2 payments
|
| Coloplast | Titan | $25 | 1 payment
|
| Profound Medical | Tulsa-Pro | $24 | 1 payment
|
| AbbVie | Botox | $22 | 1 payment
|
| Blue Earth Diagnostics | Posluma | $21 | 1 payment
|
| Axonics | Axonics | $17 | 1 payment
|
| Calyxo | Cvac Aspiration System | $15 | 1 payment
|
| Tolmar | Eligard | $14 | 1 payment
|
| Laborie Medical Technologies | None | $14 | 1 payment
|
2022: $1,539
| Teleflex | Urolift | $1,252 | 7 payments
|
| Endo Pharmaceuticals | Xiaflex | $127 | 8 payments
|
| Coloplast | Speedicath | $82 | 3 payments
|
| 180 Medical | None | $28 | 1 payment
|
| Abbvie | Botox | $18 | 1 payment
|
| Janssen Biotech | Erleada | $16 | 1 payment
|
| Astellas Pharma US | Myrbetriq | $14 | 1 payment
|
2021: $359
| Coloplast | Speedicath | $196 | 11 payments
|
| Teleflex | Urolift System | $54 | 1 payment
|
| Endo Pharmaceuticals | Xiaflex | $42 | 2 payments
|
| 180 Medical | Gentlecath | $24 | 1 payment
|
| Janssen Biotech | Erleada | $23 | 1 payment
|
| Allergan | Botox | $21 | 1 payment
|
2020: $312
| Medtronic USA | Interstim | $123 | 1 payment
|
| NeoTract | Urolift | $64 | 1 payment
|
| Allergan | Botox | $50 | 3 payments
|
| Antares Pharma | Otrexup | $29 | 2 payments
|
| Astellas Pharma US | Xtandi | $20 | 1 payment
|
| Coloplast | Continence Care | $15 | 1 payment
|
| Endo Pharmaceuticals | Aveed | $11 | 1 payment
|
2019: $665
| Coloplast | Titan | $261 | 5 payments
|
| Boston Scientific | Erectile Dysfunction | $132 | 5 payments
|
| NeoTract | Urolift | $125 | 1 payment
|
| Janssen Biotech | Erleada | $52 | 3 payments
|
| Allergan | Botox | $35 | 2 payments
|
| Pfizer | Xtandi | $28 | 2 payments
|
| Astellas Pharma US | Xtandi | $18 | 1 payment
|
| Antares Pharma | Otrexup | $15 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 98.4 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1144640855
- Licence
- FL ME139247Florida ME139247: Active
- Trained
- University of South Florida College of Medicine, 2014 · 12 years ago
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Urology (208800000X); Student in a training program (390200000X)
- Mailing address
- 2160 Colonial Blvd, Fort Myers, FL, 33907
- NPI first listed
- 2014-04-21
- NPI last updated
- 2025-03-28
- NPI record certified
- 2025-03-28
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 3325 S Tamiami Trl Ste 200, Sarasota, FL, 34239